Abstract:Background & aims: Patients with acute liver failure (ALF) have defects in innate immune responses to microbes (immune paresis) and are susceptible to sepsis. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), which interacts with the membrane receptor B7 (also called CD80 and CD86), is a negative regulator of T-cell activation. We collected T cells from patients with ALF and investigated whether inhibitory signals down-regulate adaptive immune responses in patients with ALF. Methods: We collected peripheral blood mononuclear cells from patients with ALF and controls from September 2013 through September 2015 (45 patients with ALF, 20 patients with acute-on-chronic liver failure, 15 patients with cirrhosis with no evidence of acute decompensation, 20 patients with septic shock but no cirrhosis or liver disease, and 20 healthy individuals). Circulating CD4+ T cells were isolated and analyzed by flow cytometry. CD4+ T cells were incubated with antigen, or agonist to CD3 and dendritic cells, with or without antibody against CTLA4; T-cell proliferation and protein expression were quantified. We measured levels of soluble B7 molecules in supernatants of isolated primary hepatocytes, hepatic sinusoidal endothelial cells, and biliary epithelial cells from healthy or diseased liver tissues. We also measured levels of soluble B7 serum samples from patients and controls, and mice with acetaminophen-induced liver injury using enzyme-linked immunosorbent assays. Results: Peripheral blood samples from patients with ALF had a higher proportion of CD4+ CTLA4+ T cells than controls; patients with infections had the highest proportions. CD4+ T cells from patients with ALF had a reduced proliferative response to antigen or CD3 stimulation compared to cells from controls; incubation of CD4+ T cells from patients with ALF with an antibody against CTLA4 increased their proliferative response to antigen and to CD3 stimulation, to the same levels as cells from controls. CD4+ T cells from controls up-regulated expression of CTLA4 after 24-48 hours culture with sera from patients with ALF; these sera were found to have increased concentrations of soluble B7 compared to sera from controls. Necrotic human primary hepatocytes exposed to acetaminophen, but not hepatic sinusoidal endothelial cells and biliary epithelial cells from patients with ALF, secreted high levels of soluble B7. Sera from mice with acetaminophen-induced liver injury contained high levels of soluble B7 compared to sera from mice without liver injury. Plasma exchange reduced circulating levels of soluble B7 in patients with ALF and expression of CTLA4 on T cells. Conclusions: Peripheral CD4+ T cells from patients with ALF have increased expression of CTLA4 compared to individuals without ALF; these cells have a reduced response to antigen and CD3 stimulation. We found sera of patients with ALF and from mice with liver injury to have high concentrations of soluble B7, which up-regulates CTLA4 expression by T cells and reduces their response to antigen. Plasma exchange reduces levels of B7 in sera from patients with ALF and might be used to restore antimicrobial responses to patients.

Macrophage activation markers are associated with infection and mortality in patients with acute liver failure

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

Pro-adrenomedullin in Acute Decompensation of Liver Cirrhosis: Relationship with Acute-on-chronic Liver Failure and Short-Term Survival.

Bacterial Infection and Predictors of Mortality in Patients with Autoimmune Liver Disease-Associated Acute-On-Chronic Liver Failure

Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation

Altered Immune Function Of Monocytes In Different Stages Of Patients With Acute On Chronic Liver Failure

Identification of Effective Diagnostic Biomarker and Immune Cell Infiltration Characteristics in Acute Liver Failure by Integrating Bioinformatics Analysis and Machine-Learning Strategies

Proteomic Signature of Acute Liver Failure: from Discovery and Verification in a Pig Model to Confirmation in Humans.

Characterization of the Circulating Microbiome in Acute-on-chronic Liver Failure Associated with Hepatitis B.

Deactivation and apoptosis of hepatic macrophages are involved in the development of concanavalin A‑induced acute liver failure.

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis

Transcriptomics Unveils Immune Metabolic Disruption and a Novel Biomarker of Mortality in Patients with HBV-related Acute-on-chronic Liver Failure

Serum Macrophage Inflammatory Protein 3α Levels Predict the Severity of HBV-related Acute-on-chronic Liver Failure

Soluble factors and suppressive monocytes can predict early development of sepsis in acute‐on‐chronic liver failure

Macrophage Activation Marker Soluble Cd163 Is A Dynamic Marker Of Liver Fibrogenesis In Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure

Hepatic Macrophages Are the Cell Source of Hepatic Procalcitonin in Acute Liver Failure

Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure

Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation